Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.52 |
| ▸ | CBR1 | P16152 | 1/20 | 0.52 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28920340 | 0.91 | POLB (0.69) | POLBESR2HSD17B3GPR55MIF | |
| SCHEMBL30087327 | 0.87 | POLB (0.64) | POLBESR2HSD17B3AKR1B10AKR1B1 | |
| SCHEMBL220708 | 0.82 | HSD17B3 (0.65) | POLBESR2HSD17B3AKR1B1MEN1 | |
| SCHEMBL29066603 | 0.82 | ESR2 (0.61) | POLBESR2HSD17B3AKR1B1MEN1 | |
| SCHEMBL30405545 | 0.82 | HSD17B3 (0.65) | POLBESR2HSD17B3AKR1B1MEN1 | |
| SCHEMBL6037595 | 0.81 | POLB (0.59) | POLBESR2HSD17B3AKR1B1MEN1 | |
| SCHEMBL28164061 | 0.81 | POLB (0.59) | POLBESR2HSD17B3AKR1B1MEN1 | |
| SCHEMBL16283606 | 0.81 | POLB (0.59) | POLBESR2HSD17B3AKR1B1MEN1 | |
| SCHEMBL15084975 | 0.79 | POLB (0.58) | POLBESR2HSD17B3AKR1B10AKR1B1 | |
| SCHEMBL12433441 | 0.78 | POLB (0.57) | POLBESR2HSD17B3AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | claimed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | claimed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | claimed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | POLB 4479/4885ESR2 943/4885HSD17B3 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.